Donate
  • Press Releases

Medicines360 Appoints Erica Rogers to Board of Directors

Rogers brings over 30 years of experience in the medical technology and healthcare sectors to Medicines360

SAN FRANCISCO, CALIFORNIA, April 10, 2024 – Medicines360, a global mission-driven women’s health company that focuses on developing new products and accelerating access to innovation for women, has appointed Erica Rogers to the Board of Directors, effective March 8, 2024. Ms. Rogers, an accomplished innovator and entrepreneur, brings over 30 years of experience leading high-growth health technology companies to Medicines360. She previously served as Medicines360’s Chief Operating Officer (COO) from 2010 to 2012, and on the Board as a Director from 2012 to 2014. She returns at another transformational moment in the company’s development, as Medicines360 rapidly extends its reach to serve more women in more ways across the globe.

“Medicines360 has demonstrated considerable impact, helping over 1.5 million women to date, driven by its mission to improve equitable health outcomes,” said Ms. Rogers. “I’m honored to return to the organization at this pivotal growth stage and accelerate the timeline from health innovation to access for all women.”

Ms. Rogers is a renowned medical technology industry trailblazer and entrepreneur. She served as President and CEO of Silk Road Medical from 2012 to 2023, where she successfully navigated the organization from early venture funding and clinical trials to a successful Initial Public Offering (IPO) in 2019, while simultaneously cultivating a mission-driven company culture.

Prior to Medicines360 and Silk Road Medical, Ms. Rogers co-founded two medical device companies, and is a named inventor on over 25 U.S. medical technology patents. Ms. Rogers spent over 12 years in sales and marketing roles at Boston Scientific, a global medical technology company.

“We are thrilled to welcome Erica Rogers to our Board of Directors. Ms. Rogers’ extensive experience and leadership in navigating the complex drug and device commercialization landscape will be invaluable to our organization,” said Medicines360 CEO Andrea Olariu. “She will be a key advisor to us as we expand our product portfolio offerings to address additional unmet needs in the area of women’s health.”

Ms. Rogers currently sits on the Board of Directors at HistoSonics and Sight Sciences, and serves as an Investment Advisor to Venture Investors. She previously sat on the Board of Directors of Lucira Health and served as an Advisor to Alydia Health, which was acquired by Organon in 2021. In addition, she has been a strong advocate for women in science and engineering executive roles, serving as a leader in AdvaMed’s Women’s Executive Network, among other leadership roles. She received the MedTech MVP Award in 2023, EY Entrepreneur of the Year award in 2020 and the Forbes 50 over 50 award in 2022.

Contacts:

Anna Britt
Waxman Strategies
540-808-6963
anna@waxmanstrategies.com

Heidi Glasser
Medicines360
415-951-8700
hglasser@medicines360.org

View All

About Medicines360

Located in San Francisco, California, Medicines360 is a global nonprofit pharmaceutical organization with a mission to accelerate the timeline from health innovation to access for all women. Medicines360 is committed to working with healthcare providers, advocacy groups, and patients to deliver innovative and meaningful treatments that help women around the world have greater access to the medicines they need. For more information, visit www.medicines360.org.

Share This

©2022 Medicines360. A 501(c)(3) tax-exempt organization. Medicines360® and its design are registered trademarks of Medicines360. 

Avibela® is a registered trademark of Medicines360 in countries across Africa, South and Southeast Asia, Central America, and the Caribbean.

Impact RH360® is a registered trademark of Medicines360 in Madagascar, Rwanda, Uganda, South Africa, and Zambia.

All other trademarks are property of their respective owners.

Twitter Instagram Linkedin

AVIBELA can be made available in the following 88 countries

  1. Algeria
  2. Angola
  3. Bangladesh
  4. Belize
  5. Benin
  6. Bhutan
  7. Botswana
  8. Burkina Faso
  9. Burundi
  10. Cambodia
  11. Cameroon
  12. Cape Verde
  13. Central African Republic
  14. Chad
  15. Comoros
  16. Costa Rica
  17. Cuba
  18. Democratic Republic of the Congo
  19. Djibouti
  20. Dominica
  21. Dominican Republic
  22. Egypt
  23. El Salvador
  24. Equatorial Guinea
  25. Eritrea
  26. Ethiopia
  27. Gabon
  28. Ghana
  29. Grenada
  30. Guatemala
  31. Guinea
  32. Guinea-Bissau
  33. Haiti
  34. Honduras
  35. India
  36. Indonesia
  37. Ivory Coast
  38. Jamaica
  39. Kenya
  40. Lao PDR
  41. Lesotho
  42. Liberia
  43. Libya
  44. Madagascar
  45. Malawi
  46. Malaysia
  47. Maldives
  48. Mali
  49. Mauritania
  50. Mauritius
  51. Mayotte
  52. Morocco
  53. Mozambique
  54. Myanmar
  55. Namibia
  56. Nepal
  57. Nicaragua
  58. Niger
  59. Nigeria
  60. Pakistan
  61. Panama
  62. Papua New Guinea
  63. Philippines
  64. Republic of the Congo
  65. Rwanda
  66. Sao Tome and Principe
  67. Senegal
  68. Seychelles
  69. Sierra Leone
  70. Somalia
  71. South Africa
  72. South Sudan
  73. Sri Lanka
  74. Kitts and Nevis
  75. Lucia
  76. Vincent & the Grenadines
  77. Sudan
  78. Swaziland
  79. Tanzania
  80. Thailand
  81. The Gambia
  82. Timor-Leste
  83. Togo
  84. Tunisia
  85. Uganda
  86. Vietnam
  87. Zambia
  88. Sri Lanka

Tina Raine-Bennett, MD, MPH, FACOG

Chief Executive Officer

Tina Raine-Bennett, MD, MPH, is CEO of Medicines360. Previously, she served as a senior research scientist at the Kaiser Permanente Northern California Division of Research and the research director of the Women’s Health Research Institute. She is a Board-Certified Obstetrician Gynecologist who received her medical training at the University of California, San Diego, and post-graduate residency training and MPH at the University of Washington in Seattle, where she also completed a Robert Wood Johnson Clinical Scholars Fellowship. She was also senior staff physician at Kaiser Permanente and has a special interest in family planning and adolescent reproductive health.

As the director of the Women’s Health Research Institute, Dr. Raine-Bennett focused on expanding research on women’s health within the Division and translating women’s health research into clinical practice and policy within the Ob/Gyn departments in Northern California. She also promoted the involvement of clinicians in research designed to improve the health outcomes and healthcare experiences of women at Kaiser Permanente and women in general.

Prior to Kaiser Permanente, Dr. Raine-Bennett was a professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at University of California, San Francisco (UCSF). She was based at San Francisco General Hospital where she was also the medical director of the New Generation Health Center, a UCSF affiliate site that provides community-based reproductive health services. Dr. Raine-Bennett’s research has focused on contraceptive methods and on elucidating factors that influence contraceptive choice and continuation, and she was principal investigator on NIH grants to assess hormonal contraceptive use predictors and develop interventions to improve contraceptive access.

Her past and current research on emergency contraception has focused on the safety of making emergency contraception more accessible and she conducted a pivotal clinical trial to make emergency contraception available to teens without a prescription. She served on the editorial board of Obstetrics and Gynecology and has over 100 peer-reviewed publications. She was the Treasurer of the Board of Directors for the Society of Family Planning and Society of Family Planning Research Fund. She has also served as an examiner for the American Board of Obstetrics and Gynecology, and on national committees for the American College of Obstetrics and Gynecology and the National Medical Board of Planned Parenthood Federation of America.